Gerald L. Ray & Associates’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
$22.5M Sell
120,452
-457
-0.4% -$81K 2.8% 5
2017
Q2
$20.8M Sell
120,909
-1,610
-1% -$262K 2.69% 5
2017
Q1
$20.1M Sell
122,519
-530
-0.4% -$88.1K 2.75% 5
2016
Q4
$18M Sell
123,049
-305
-0.2% -$45.9K 2.61% 5
2016
Q3
$20.6M Buy
123,354
+1,538
+1% +$260K 3.09% 4
2016
Q2
$18.5M Sell
121,816
-667
-0.5% -$104K 2.96% 4
2016
Q1
$18.4M Buy
122,483
+1,727
+1% +$257K 2.98% 5
2015
Q4
$19.6M Sell
120,756
-430
-0.4% -$67.6K 3.1% 4
2015
Q3
$16.8M Sell
121,186
-258
-0.2% -$40.7K 2.8% 5
2015
Q2
$18.6M Buy
121,444
+140
+0.1% +$22.4K 2.84% 5
2015
Q1
$19.4M Sell
121,304
-540
-0.4% -$85K 2.92% 5
2014
Q4
$19.4M Sell
121,844
-500
-0.4% -$77.9K 2.98% 4
2014
Q3
$17.2M Sell
122,344
-715
-0.6% -$93.4K 2.8% 5
2014
Q2
$14.6M Sell
123,059
-100
-0.1% -$11.6K 2.48% 5
2014
Q1
$15.2M Buy
123,159
+180
+0.1% +$21.8K 2.75% 4
2013
Q4
$14M Sell
122,979
-250
-0.2% -$28.4K 2.64% 4
2013
Q3
$13.8M Sell
123,229
-1,560
-1% -$169K 2.85% 3
2013
Q2
$12.3M Buy
+124,789
New +$12.9M 2.76% 3

Other funds holding AMGN

Gerald L. Ray & Associates's AMGN Position: Q3 2017 in Review

Gerald L. Ray & Associates reduced its Amgen (AMGN) stake by 0.38% in Q3 2017, selling an estimated $81K and leaving 120,452 shares worth $22.5M. The position accounts for 2.8% of the portfolio, ranked #5.

Gerald L. Ray & Associates first reported a position in AMGN in Q2 2013 and has held it in 18 quarters since. 1,605 funds tracked by Wall St. Rank hold AMGN as of Q3 2017.

  • Gerald L. Ray & Associates held 120,452 shares of Amgen worth $22.5M as of Q3 2017.
  • Gerald L. Ray & Associates sold 457 Amgen shares in Q3 2017, an estimated $81K.
  • Amgen made up 2.8% of Gerald L. Ray & Associates's portfolio in Q3 2017, its #5 holding.
  • Gerald L. Ray & Associates first reported a position in Amgen in Q2 2013 and has held it in 18 quarters since.
  • 1,605 funds tracked by Wall St. Rank held Amgen as of Q3 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.